Featured Research

from universities, journals, and other organizations

New Radiotherapy Regime Benefits Young Women With Breast Cancer

Date:
November 4, 2004
Source:
Federation Of European Cancer Societies
Summary:
Women under 35 years of age with breast cancer can have an almost 20% lower risk of their disease recurring if they are treated using a new radiotherapy regime. These were some of the results presented here today (Tuesday 26th October) by Prof. Harry Bartelink and his colleagues at the 23rd Meeting of the European Society for Therapeutic Radiology and Oncology.

Women under 35 years of age with breast cancer can have an almost 20% lower risk of their disease recurring if they are treated using a new radiotherapy regime. These were some of the results presented here today (Tuesday 26th October) by Prof. Harry Bartelink and his colleagues at the 23rd Meeting of the European Society for Therapeutic Radiology and Oncology.

The analyses were based on data from the EORTC (European Organisation for Research and Treatment of Cancer) 22881 trial with updated follow-up (median follow-up: > 6years). 5318 patients with microscopically complete excision of early breast cancer using breast-conserving surgery were randomly assigned to undergo 50Gy irradiation of the whole breast either with or without an additional 16Gy of radiotherapy to the tumour bed (radiotherapy boost). 362 local recurrences were observed: 232 in the no-boost group and 130 in the boost group, demonstrating a considerable improvement in recurrence rate in women treated with boost.

The effect of the boost treatment was of greatest benefit in the younger women, with a reduction in 5-year local disease recurrence rate from 26% to 8.5% in women under 35 years of age. In women over 60 the boost dose resulted in a reduction of 5-year local recurrence rate from 3.9% to 2.1%. The addition of a boost dose caused a slight increase in early and late side effects and increases the burden on already overstretched resources. A balance therefore needs to be struck between providing optimal care with acceptable side effects whilst taking into account the availability of resources.

The trial data was used to estimate the impact on the 5-year local recurrence rate of a treatment policy restricting boost irradiation to patients below a certain age threshold. If no patients received a boost then the overall local recurrence rate would be 6.5%, whilst treating all patients with a boost would result in a recurrence rate of 3.6%. A policy limiting the boost dose to patients 40 years old or younger (or 8.4% of the total) would result in an overall 5-year local recurrence of 5.7% in the whole population. By increasing the threshold to 50 years (boost given to 34% of the total) the 5-year local recurrence rate reduces further to 4.8% - equivalent to the local control achieved by mastectomy.

"This evidence suggests that a 16Gy boost is a tolerable and viable alternative to total mastectomy, achieving similar local recurrence rates as the latter whilst sparing patients the necessity of breast removal", said Prof. Bartelink. "These results are so conclusive that this new approach should be immediately implemented in cancer treatment centres as a new standard of care for women under 51 years old".

"Increasing the amount of radiation given in the boost dose for younger patients, those 50 years old or younger, may improve the results even further. This is currently being investigated in a new trial", said Prof. Bartelink. "Another trial, using microarray molecular technology, is also underway which aims to develop techniques which will predict how individual women will respond to radiotherapy and therefore predict which women should receive a boost dose".


Story Source:

The above story is based on materials provided by Federation Of European Cancer Societies. Note: Materials may be edited for content and length.


Cite This Page:

Federation Of European Cancer Societies. "New Radiotherapy Regime Benefits Young Women With Breast Cancer." ScienceDaily. ScienceDaily, 4 November 2004. <www.sciencedaily.com/releases/2004/10/041030183026.htm>.
Federation Of European Cancer Societies. (2004, November 4). New Radiotherapy Regime Benefits Young Women With Breast Cancer. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2004/10/041030183026.htm
Federation Of European Cancer Societies. "New Radiotherapy Regime Benefits Young Women With Breast Cancer." ScienceDaily. www.sciencedaily.com/releases/2004/10/041030183026.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins